Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Other Non-Current Assets (2022 - 2025)

Taysha Gene Therapies (TSHA) has disclosed Other Non-Current Assets for 4 consecutive years, with $2.8 million as the latest value for Q4 2025.

  • Quarterly Other Non-Current Assets rose 6.31% to $2.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.8 million through Dec 2025, up 6.31% year-over-year, with the annual reading at $2.8 million for FY2025, 6.31% up from the prior year.
  • Other Non-Current Assets hit $2.8 million in Q4 2025 for Taysha Gene Therapies, up from $2.2 million in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $2.8 million in Q4 2025 to a low of $304000.0 in Q4 2023.
  • Historically, Other Non-Current Assets has averaged $2.3 million across 4 years, with a median of $2.6 million in 2024.
  • Biggest five-year swings in Other Non-Current Assets: tumbled 76.9% in 2023 and later skyrocketed 755.26% in 2024.
  • Year by year, Other Non-Current Assets stood at $1.3 million in 2022, then crashed by 76.9% to $304000.0 in 2023, then surged by 755.26% to $2.6 million in 2024, then grew by 6.31% to $2.8 million in 2025.
  • Business Quant data shows Other Non-Current Assets for TSHA at $2.8 million in Q4 2025, $2.2 million in Q3 2025, and $2.2 million in Q2 2025.